Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-10-02-2004, Volume 28, Issue 10

Big Pharma is ramping up capital spending in parenteral manufacturing at the same time that contract manufacturers are completing their own major investment programs.

Related Content:

Drug DeliveryBio/Pharma BusinessOutsourcingManufacturingOutsourcing OutlookDevelopmentParenteralsDosage FormsManufacturing, Parenterals and InjectablesManufacturing, Drug ProductsPharmaceutical Technology-10-02-2004
2023 Nobel Prize in Medicine Awarded for Development of mRNA Vaccines Against COVID-19
Pfizer and Ginkgo Bioworks to Collaborate on Multi-Target RNA Discovery
Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions Business